Brief: Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
22/08/2024 14:19
Aug 22 (Reuters) - Cadrenal Therapeutics Inc CVKD.O :
* CADRENAL THERAPEUTICS ANNOUNCES UPCOMING TYPE-B FDA
MEETING IN
SEPTEMBER TO DISCUSS TECARFARIN TRIAL IN LVAD PATIENTS
Source text for Eikon: ID:nPnbrWwS8a
Further company coverage: CVKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology